BRPI0611820B8 - método de identificar uma infecção por e. canis ou e. chaffeensis - Google Patents

método de identificar uma infecção por e. canis ou e. chaffeensis

Info

Publication number
BRPI0611820B8
BRPI0611820B8 BRPI0611820A BRPI0611820A BRPI0611820B8 BR PI0611820 B8 BRPI0611820 B8 BR PI0611820B8 BR PI0611820 A BRPI0611820 A BR PI0611820A BR PI0611820 A BRPI0611820 A BR PI0611820A BR PI0611820 B8 BRPI0611820 B8 BR PI0611820B8
Authority
BR
Brazil
Prior art keywords
chaffeensis
kennels
infection
identifying
compositions
Prior art date
Application number
BRPI0611820A
Other languages
English (en)
Inventor
Kuyler Doyle Christopher
W Mcbride Jere
Original Assignee
Res Found Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Found Dev filed Critical Res Found Dev
Publication of BRPI0611820A2 publication Critical patent/BRPI0611820A2/pt
Publication of BRPI0611820B1 publication Critical patent/BRPI0611820B1/pt
Publication of BRPI0611820B8 publication Critical patent/BRPI0611820B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1246—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Rickettsiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/29—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Richettsiales (o)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

composição isolada, polinucleotídeo e anticorpo isolado. a presente invenção refere-se a composições imunorreativas de gp36 para e. anis e composições irrunorreativas de gp47 para e. chaffeensis. em particular, epítopos para gp36 de e. canis e gp47 de e. chaffeensis são divulgados. em certas modalidades, as composições imunorreativas compreendem repetições em tandem tendo porções de carboidrato.
BRPI0611820A 2005-06-16 2006-06-15 método de identificar uma infecção por e. canis ou e. chaffeensis BRPI0611820B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69105805P 2005-06-16 2005-06-16
US60/691.058 2005-06-16
US60/691,058 2005-06-16
PCT/US2006/023397 WO2006138509A2 (en) 2005-06-16 2006-06-15 Immunoreactive protein orthologs of ehrlichia canis and e. chaffeensis

Publications (3)

Publication Number Publication Date
BRPI0611820A2 BRPI0611820A2 (pt) 2010-09-28
BRPI0611820B1 BRPI0611820B1 (pt) 2020-09-15
BRPI0611820B8 true BRPI0611820B8 (pt) 2021-05-25

Family

ID=37215980

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0611820A BRPI0611820B8 (pt) 2005-06-16 2006-06-15 método de identificar uma infecção por e. canis ou e. chaffeensis

Country Status (6)

Country Link
US (6) USRE46254E1 (pt)
EP (1) EP1891095A2 (pt)
BR (1) BRPI0611820B8 (pt)
CA (1) CA2612302C (pt)
MX (1) MX2007016189A (pt)
WO (1) WO2006138509A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087372B2 (en) 2001-01-18 2006-08-08 Idexx Laboratories, Inc. Compositions and methods for detection of Ehrlichia canis and Ehrlichia chaffeensis antibodies
US7407770B2 (en) 2001-01-18 2008-08-05 Idexx Corporation Compositions and methods for detection of Ehrlichia canis and Ehrlichia chaffeensis antibodies
US7842474B2 (en) * 2005-04-04 2010-11-30 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)
US7842473B2 (en) 2005-04-04 2010-11-30 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)
WO2009039414A2 (en) 2007-09-21 2009-03-26 Idexx Laboratories, Inc. Methods and compositions for detection of ehrlichia chaffeensis (vlpt)
EP2203469A4 (en) 2007-09-21 2011-08-24 Idexx Lab Inc METHOD AND COMPOSITIONS FOR IDENTIFYING EHRLICHIA CHAFFEENSIS (P120)
EP3527221B1 (en) 2007-10-31 2022-02-23 Idexx Laboratories, Inc. Ehrlichia canis diva (differentiate infected from vaccinated animals)
WO2010126993A1 (en) * 2009-04-28 2010-11-04 Research Development Foundation Immunoreactive ehrlichia p120/p140 epitopes and uses thereof
ES2596952T3 (es) 2009-11-20 2017-01-13 Abaxis, Inc. Péptidos, dispositivos y procedimientos para la detección de anticuerpos de Ehrlichia
US10100092B2 (en) * 2011-11-03 2018-10-16 Vca, Inc. Compositions and methods to detect various infectious organisms
US9133525B2 (en) 2012-01-26 2015-09-15 Luc Montagnier Detection of DNA sequences as risk factors for HIV infection
BR112015008036B1 (pt) 2012-10-11 2022-09-13 Zoetis Services Llc População de peptídeos isolados, método para detectar em uma amostra um anticorpo, método para diagnosticar erliquiose monocítica e/ou granulocítica, método para detectar a presença de anticorpos e kit
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
US9194870B2 (en) 2014-01-21 2015-11-24 Abaxis, Inc. Peptides, devices, and methods for the detection of Anaplasma antibodies
US9442112B2 (en) 2014-04-04 2016-09-13 Abaxis, Inc. Compositions and methods for identifying Ehrlichia species
MX2020011887A (es) * 2018-05-07 2021-03-29 Res Found Dev Polipéptidos inmunorreactivos.
EP3996741A1 (en) * 2019-07-12 2022-05-18 Research Development Foundation Ehrlichia vaccines and immunogenic compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1581638B1 (en) * 2002-11-04 2007-09-05 Research Development Foundation P153 and p156 antigens for the immunodiagnosis of canine and human ehrlichioses and uses thereof

Also Published As

Publication number Publication date
US20140127721A1 (en) 2014-05-08
BRPI0611820A2 (pt) 2010-09-28
WO2006138509A3 (en) 2007-02-15
USRE46254E1 (en) 2016-12-27
US20100183654A1 (en) 2010-07-22
US9140702B2 (en) 2015-09-22
WO2006138509A2 (en) 2006-12-28
US20200199205A1 (en) 2020-06-25
MX2007016189A (es) 2008-03-10
BRPI0611820B1 (pt) 2020-09-15
US20170204168A1 (en) 2017-07-20
CA2612302C (en) 2015-07-28
EP1891095A2 (en) 2008-02-27
CA2612302A1 (en) 2006-12-28
US20160084836A1 (en) 2016-03-24
US11459379B2 (en) 2022-10-04
US8591906B2 (en) 2013-11-26
US9645148B2 (en) 2017-05-09

Similar Documents

Publication Publication Date Title
BRPI0611820B8 (pt) método de identificar uma infecção por e. canis ou e. chaffeensis
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
BRPI0618451A2 (pt) derivados de piridopirazina, seu uso, composição farmacêutica e estojo
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
CO6382140A2 (es) Composiciones de vacuna que comprenden una proteina de enlace del factor h mutada
MY174493A (en) Binding agents
WO2010043977A3 (en) Dengue virus neutralizing antibodies and uses thereof
CR9253A (es) Fijacion de la dosificacion de anticuerpos her
CL2013001673A1 (es) Composicion acuosa que comprende aproximadamente 18% p/v de concentracion, donde al menos el 95% de las proteinas son igg; metodo mejorado para preparar dicha composición.
EA200802168A1 (ru) Гуманизированное антитело к с-kit
EA201100300A1 (ru) Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента
MX2009006471A (es) Anticuerpo anti especifico de linfopoyetina estromal timica de diseño.
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
EA201001639A1 (ru) Композиции и способы их получения и применения
EA201790757A1 (ru) Связывающие антиген cd27l белки
EA200800812A1 (ru) Композиции антитела против cd3
AR077016A1 (es) Uso de un anticuerpo anti-tau ps422 para el tratamiento de enfermedades cerebrales
EA200970471A1 (ru) Микроорганизмы или их фракции, обеспечивающие активацию клеточного иммунитета против углеводов
EA200702532A1 (ru) Антитела против мср-1, композиции, способы и применения
BRPI0711889B8 (pt) método para produção de sinvastatina, composição de matéria, método para fabricação de huvastatina, método para fabricação de sinvastatina, e método para fabricação de uma composição de matéria de sinvastatina ou huvastatina
GT200600224A (es) Metodos para purificar tigeciclina
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/06/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF